ACAD
26.02
-0.25
-0.95%
AEMD
1.874
+0.064
+3.5193%
APRI
0.95
-0.01
-1.04%
ARNA
1.31
-0.05
-3.68%
ATEC
1.99
-0.04
-1.97%
CNAT
5.17
-0.09
-1.71%
CRXM
0.161
-0.009
-5.4118%
CYTX
1.03
0.00
0.00%
DXCM
68.65
-0.5
-0.72%
GNMK
13.14
+0.14
+1.08%
HALO
12.41
-0.19
-1.51%
ILMN
175.91
+2.15
+1.24%
INNV
0.133
+0.015
+12.807%
INO
7.88
-0.11
-1.38%
ISCO
1.32
-0.17
-11.41%
ISIS
57.56
0.00
0.00%
LGND
110.19
-3.31
-2.92%
LPTN
2.93
0.00
0.00%
MBVX
1.66
-0.13
-7.26%
MEIP
2.12
+0.15
+7.61%
MNOV
5.95
-0.1
-1.65%
MRTX
3.25
-0.05
-1.52%
MSTX
0.131
0.00
0.00%
NBIX
46.22
-2.42
-4.99%
NUVA
75.52
-0.26
-0.34%
ONCS
1.06
+0.08
+8.16%
ONVO
2.94
+0.09
+3.16%
OREX
2.97
+0.03
+1.02%
OTIC
12.35
-0.3
-2.37%
QDEL
24.91
-0.01
-0.04%
RCPT
231.96
0.00
0.00%
RGLS
1.375
+0.025
+1.852%
RMD
70.07
+0.02
+0.03%
SCIE
0.001
+0.00
+16.6667%
SPHS
2.46
-0.01
-0.40%
SRNE
1.75
+0.1
+6.06%
TROV
0.651
-0.039
-5.6377%
VICL
2.36
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
12.65
-0.25
-1.94%
ACAD
26.02
-0.25
-0.95%
AEMD
1.874
+0.064
+3.5193%
APRI
0.95
-0.01
-1.04%
ARNA
1.31
-0.05
-3.68%
ATEC
1.99
-0.04
-1.97%
CNAT
5.17
-0.09
-1.71%
CRXM
0.161
-0.009
-5.4118%
CYTX
1.03
0.00
0.00%
DXCM
68.65
-0.5
-0.72%
GNMK
13.14
+0.14
+1.08%
HALO
12.41
-0.19
-1.51%
ILMN
175.91
+2.15
+1.24%
INNV
0.133
+0.015
+12.807%
INO
7.88
-0.11
-1.38%
ISCO
1.32
-0.17
-11.41%
ISIS
57.56
0.00
0.00%
LGND
110.19
-3.31
-2.92%
LPTN
2.93
0.00
0.00%
MBVX
1.66
-0.13
-7.26%
MEIP
2.12
+0.15
+7.61%
MNOV
5.95
-0.1
-1.65%
MRTX
3.25
-0.05
-1.52%
MSTX
0.131
0.00
0.00%
NBIX
46.22
-2.42
-4.99%
NUVA
75.52
-0.26
-0.34%
ONCS
1.06
+0.08
+8.16%
ONVO
2.94
+0.09
+3.16%
OREX
2.97
+0.03
+1.02%
OTIC
12.35
-0.3
-2.37%
QDEL
24.91
-0.01
-0.04%
RCPT
231.96
0.00
0.00%
RGLS
1.375
+0.025
+1.852%
RMD
70.07
+0.02
+0.03%
SCIE
0.001
+0.00
+16.6667%
SPHS
2.46
-0.01
-0.40%
SRNE
1.75
+0.1
+6.06%
TROV
0.651
-0.039
-5.6377%
VICL
2.36
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
12.65
-0.25
-1.94%
Home » Archive by Category

Xconomy

Biotech Roundup: JPM Deals, Gender Diversity, PCSK9 Battle & More

January 13, 2017 – 6:07 am

[Corrected, 1/14/16, see below] This past week, the biopharma industry made its annual January pilgrimage to San Francisco for the J.P. Morgan Healthcare Conference. 2016 was a whirlwind year in…

[[Click headline to continue reading.]]

Notes From The JPM ’17 Vortex: Trump, Rainstorms & The Price You Pay

January 13, 2017 – 3:33 am

[Editor’s note: Ben Fidler contributed to this report] The week of frenetic data sharing, deal talking, and party hopping of the J.P. Morgan Healthcare Conference—and the events that have…

[[Click headline to continue reading.]]

Biopharma Leaders Call for Gender Diversity Amid J.P. Morgan Conference

January 11, 2017 – 12:00 pm

A group of more than 100 prominent life sciences executives, investors, and business leaders have signed an open letter calling on the industry to step up efforts to increase gender diversity. The…

[[Click headline to continue reading.]]

Correlation Ventures Raises $200M, Maintains Its “Moneyball” Strategy

January 11, 2017 – 11:33 am

Correlation Ventures, a co-investing venture firm that uses analytic software to optimize its decisions, said today it has raised $200 million for its oversubscribed second fund. The firm, which has…

[[Click headline to continue reading.]]

Trump Slams Drug Companies, Says Medicare “Bidding” Is Coming

January 11, 2017 – 10:46 am

Oh, the power of a Donald Trump sound bite. On the campaign trail and as president-elect he has made occasional noises about drug pricing—giving the U.S. Medicare system, the largest buyer of…

[[Click headline to continue reading.]]

At Allergan And Other Pharmas, Price Transparency Has Limits

January 11, 2017 – 3:30 am

The first test of pharmaceutical giant Allergan’s promise to behave responsibly came last week. The firm acknowledged price hikes on several drugs that stayed—sometimes barely—under…

[[Click headline to continue reading.]]

J&J, NY State to Form Biotech Incubator in Big Apple’s Genome Center

January 9, 2017 – 3:47 pm

New York State Governor Andrew Cuomo is planning to use some of the cash from his recently announced $650 million biotech initiative on Manhattan’s biggest life sciences problem—lack of lab…

[[Click headline to continue reading.]]

Bio Roundup: Biogen Price Fears, A Grail Billion, Hellos, Byes & More

January 6, 2017 – 3:35 am

Happy new year, everyone. Are you all strapped in? Tray tables in the locked and upright position? As Bette Davis once said, “It’s going to be a bumpy night.” The news from…

[[Click headline to continue reading.]]

Families Fret As Insurers Mull Biogen’s $750K Spine Disease Drug

January 6, 2017 – 2:45 am

This past Christmas weekend, Ana Memedovich had her best two days in more than a decade. Her 23-year-old son Mikhail has spinal muscular atrophy, or SMA, a rare genetic disease that has slowly robbed…

[[Click headline to continue reading.]]

Biopharma Industry, Heal Thyself (Without Government Help)

January 6, 2017 – 12:40 am

With the inauguration of Donald Trump as president on January 20th, the editors asked some of our Xconomists to offer their thoughts on “How could the incoming administration significantly affect…

[[Click headline to continue reading.]]